- Oyster Point Pharma, Inc.

Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference

Read more about Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference

Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Read more about Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers

Read more about Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers

Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)

Read more about Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)

Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference

Read more about Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference

Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting

Read more about Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting

Oyster Point Pharma Reports Third Quarter 2020 Financial Results and Recent Business Highlights

Read more about Oyster Point Pharma Reports Third Quarter 2020 Financial Results and Recent Business Highlights

Oyster Point Pharma to Report Third Quarter 2020 Financial Results on November 5, 2020

Read more about Oyster Point Pharma to Report Third Quarter 2020 Financial Results on November 5, 2020

Michael G. Atieh

Chair of the Audit Committee

Michael G. Atieh

Financial Expert

Oyster Point Pharma Announces Board of Directors Leadership Changes and New Appointment as the Company Advances into Next Phase of Growth

Read more about Oyster Point Pharma Announces Board of Directors Leadership Changes and New Appointment as the Company Advances into Next Phase of Growth

Information Requests

© 2021 Oyster Point Pharma, Inc. Oyster Point^™ and the Oyster Point logo are trademarks of Oyster Point Pharma, Inc.